A Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab at the Fixed Dose 40 mg, Ifosfamide, Carboplatin, Etoposide (NICE-40) in Patients With Relapsed/Refractory Hodgkin Lymphoma

Last updated: April 11, 2023
Sponsor: St. Petersburg State Pavlov Medical University
Overall Status: Active - Recruiting

Phase

1/2

Condition

Platelet Disorders

Lymphoma

Hematologic Cancer

Treatment

N/A

Clinical Study ID

NCT04981899
r/r cHL NICE-40
  • Ages 18-70
  • All Genders

Study Summary

Nivolumab is an anti-PD-1 antibody highly effective in patients with relapsed/refractory classical Hodgkin lymphoma. A PET-adapted regimen of Nivo combined with ICE as first salvage therapy was shown to induce high response rates and favorable progression-free survival as a bridge to autologous stem cell transplantation, allowing to omit salvage chemotherapy in a substantial proportion of r\r cHL patients. This study evaluates the safety and efficacy of PET-adapted treatment of nivolumab at the fixed dose of 40 mg in combination with ifosfamide, carboplatin, and etoposide (NICE-40) in patients with relapsed/refractory Hodgkin Lymphoma.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Diagnosis: Histologically confirmed Hodgkins lymphoma
  • Relapsed or refractory disease after the first line of treatment
  • Age 18-70 years old
  • Ejection fraction greater than 50%
  • ECOG 0-2 status
  • Signed informed consent
  • No severe concurrent illness

Exclusion

Exclusion Criteria:

  • Uncontrolled bacterial or fungal infection at the time of enrollment
  • Requirement for vasopressor support at the time of enrollment
  • Severe organ failure: creatinine more than 2 norms; ALT, AST more than 5 norms;bilirubin more than 1.5 norms
  • Karnofsky index <30%
  • Pregnancy
  • Somatic or psychiatric disorder making the patient unable to sign an informed consent
  • Active or prior documented autoimmune disease requiring systemic treatment.

Study Design

Total Participants: 30
Study Start date:
March 01, 2021
Estimated Completion Date:
October 01, 2024

Connect with a study center

  • National Medicine Research Center of oncology named after N.N. Petrov

    Saint Petersburg, Pesochny 197758
    Russian Federation

    Active - Recruiting

  • Irkutsk Regional Cancer Center

    Irkutsk, 664044
    Russian Federation

    Active - Recruiting

  • St. Petersburg State Pavlov Medical University

    Saint Petersburg, 197022
    Russian Federation

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.